WO1998010787A3 - Therapie a but immunitaire - Google Patents
Therapie a but immunitaire Download PDFInfo
- Publication number
- WO1998010787A3 WO1998010787A3 PCT/IB1997/001086 IB9701086W WO9810787A3 WO 1998010787 A3 WO1998010787 A3 WO 1998010787A3 IB 9701086 W IB9701086 W IB 9701086W WO 9810787 A3 WO9810787 A3 WO 9810787A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immune
- host
- interleukin
- sequences
- disease
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000003814 Interleukin-10 Human genes 0.000 abstract 4
- 108090000174 Interleukin-10 Proteins 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 229940076144 interleukin-10 Drugs 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000003278 mimic effect Effects 0.000 abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002458 infectious effect Effects 0.000 abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 102000003946 Prolactin Human genes 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000003491 array Methods 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000008004 immune attack Effects 0.000 abstract 1
- 230000008102 immune modulation Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 238000011081 inoculation Methods 0.000 abstract 1
- 210000003563 lymphoid tissue Anatomy 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12880697A IL128806A0 (en) | 1996-09-11 | 1997-09-10 | Compositions for immune therapy |
AU41320/97A AU4132097A (en) | 1996-09-11 | 1997-09-10 | Immune direction therapy |
JP51343598A JP2001503613A (ja) | 1996-09-11 | 1997-09-10 | 免疫管理療法 |
EP97939105A EP0929568A2 (fr) | 1996-09-11 | 1997-09-10 | Compositions pharmaceutiques pour therapie a but immunitaire |
CA002265885A CA2265885A1 (fr) | 1996-09-11 | 1997-09-10 | Therapie a but immunitaire |
NZ335039A NZ335039A (en) | 1996-09-11 | 1997-09-10 | Enhancing immune response by administering antibody raised to amino acid sequences with specific ion bridge pair arrays |
SE9900812A SE9900812L (sv) | 1996-09-11 | 1999-03-08 | Riktad immunoterapi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2518096P | 1996-09-11 | 1996-09-11 | |
US60/025,180 | 1996-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998010787A2 WO1998010787A2 (fr) | 1998-03-19 |
WO1998010787A3 true WO1998010787A3 (fr) | 1998-07-30 |
Family
ID=21824510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/000945 WO1998010792A1 (fr) | 1996-09-11 | 1996-09-13 | Therapie a but immunitaire |
PCT/IB1997/001086 WO1998010787A2 (fr) | 1996-09-11 | 1997-09-10 | Therapie a but immunitaire |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/000945 WO1998010792A1 (fr) | 1996-09-11 | 1996-09-13 | Therapie a but immunitaire |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0929568A2 (fr) |
JP (1) | JP2001503613A (fr) |
CN (1) | CN1230195A (fr) |
AU (2) | AU6887096A (fr) |
CA (1) | CA2265885A1 (fr) |
IL (1) | IL128806A0 (fr) |
NZ (1) | NZ335039A (fr) |
SE (1) | SE9900812L (fr) |
WO (2) | WO1998010792A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283165B2 (en) | 2008-09-12 | 2012-10-09 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
US8431384B2 (en) | 2004-05-24 | 2013-04-30 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5297299A (en) * | 1998-08-17 | 2000-03-06 | Patrick T. Prendergast | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use |
WO2000035472A2 (fr) * | 1998-12-15 | 2000-06-22 | Hollis-Eden Pharmaceuticals, Inc. | Cytokinotherapie combinee |
EP1265634A4 (fr) * | 2000-03-14 | 2005-12-28 | Nat Jewish Med & Res Center | Procede et composition pour traiter une hyperreactivite bronchique |
FI118263B (fi) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
EA008925B1 (ru) * | 2004-12-14 | 2007-08-31 | Товарищество С Ограниченной Ответственностью "Реал Мед Компани" | Способ коррекции иммунного состояния организма при сахарном диабете |
US7989590B2 (en) * | 2005-03-22 | 2011-08-02 | Rohto Pharmaceutical Co., Ltd | Peptides that increase collagen or hyaluronic acid production |
US7553932B1 (en) | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
US9850278B2 (en) | 2013-04-25 | 2017-12-26 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
CN103275222B (zh) * | 2013-05-15 | 2014-04-16 | 中山康方生物医药有限公司 | 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用 |
CN114163493B (zh) * | 2021-11-18 | 2023-09-15 | 浙大宁波理工学院 | 一种可作为5型磷酸二酯酶抑制剂的多肽及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0056249A2 (fr) * | 1981-01-09 | 1982-07-21 | New York Blood Center, Inc. | Composition synthétique d'antigènes et leur procédé de préparation |
WO1988005783A1 (fr) * | 1987-01-28 | 1988-08-11 | Ortho Pharmaceutical Corporation | Peptides immunodepresseurs et leurs procedes d'utilisation |
EP0287226A1 (fr) * | 1987-03-23 | 1988-10-19 | Hiver Limited | Vaccin |
US4822606A (en) * | 1986-04-07 | 1989-04-18 | Duke University | Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences |
EP0323424A2 (fr) * | 1987-12-30 | 1989-07-05 | Jonas Blomberg | Peptides correspondant à HIV-env 583-599, leurs analogues et utilisation de ces peptides |
WO1991014451A1 (fr) * | 1990-03-26 | 1991-10-03 | Schering Corporation | Antagonistes contre la proteine bcrf1 destines au traitement d'infections provoquees par le virus d'epstein-barr |
WO1993011157A1 (fr) * | 1991-11-27 | 1993-06-10 | The Council Of The Queensland Institute Of Medical Research | VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX) |
WO1995004075A1 (fr) * | 1993-07-28 | 1995-02-09 | Medvet Science Pty. Ltd. | Antagonistes de facteurs de croissance hematopoietique |
WO1995019568A1 (fr) * | 1994-01-14 | 1995-07-20 | Matthias Rath | Oligopeptides signaux hydrophiles et leurs procedes d'utilisation a des fins therapeutiques |
WO1997026279A1 (fr) * | 1996-01-18 | 1997-07-24 | Steeno Research Group A/S | Analogues synthetiques d'il-10 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA931489B (en) * | 1992-03-04 | 1993-10-28 | Schering Corp | Use of interleuken-10 to suppress graft-vs-host disease |
WO1993018783A1 (fr) * | 1992-03-20 | 1993-09-30 | Schering Corporation | Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1 |
CA2144648A1 (fr) * | 1992-09-18 | 1994-03-31 | Mario Clerici | Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih |
-
1996
- 1996-09-13 AU AU68870/96A patent/AU6887096A/en not_active Abandoned
- 1996-09-13 WO PCT/IB1996/000945 patent/WO1998010792A1/fr active Application Filing
-
1997
- 1997-09-10 IL IL12880697A patent/IL128806A0/xx unknown
- 1997-09-10 WO PCT/IB1997/001086 patent/WO1998010787A2/fr not_active Application Discontinuation
- 1997-09-10 JP JP51343598A patent/JP2001503613A/ja active Pending
- 1997-09-10 NZ NZ335039A patent/NZ335039A/en unknown
- 1997-09-10 EP EP97939105A patent/EP0929568A2/fr not_active Withdrawn
- 1997-09-10 CA CA002265885A patent/CA2265885A1/fr not_active Abandoned
- 1997-09-10 AU AU41320/97A patent/AU4132097A/en not_active Abandoned
- 1997-09-10 CN CN97197816A patent/CN1230195A/zh active Pending
-
1999
- 1999-03-08 SE SE9900812A patent/SE9900812L/xx not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0056249A2 (fr) * | 1981-01-09 | 1982-07-21 | New York Blood Center, Inc. | Composition synthétique d'antigènes et leur procédé de préparation |
US4822606A (en) * | 1986-04-07 | 1989-04-18 | Duke University | Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences |
WO1988005783A1 (fr) * | 1987-01-28 | 1988-08-11 | Ortho Pharmaceutical Corporation | Peptides immunodepresseurs et leurs procedes d'utilisation |
EP0287226A1 (fr) * | 1987-03-23 | 1988-10-19 | Hiver Limited | Vaccin |
EP0323424A2 (fr) * | 1987-12-30 | 1989-07-05 | Jonas Blomberg | Peptides correspondant à HIV-env 583-599, leurs analogues et utilisation de ces peptides |
WO1991014451A1 (fr) * | 1990-03-26 | 1991-10-03 | Schering Corporation | Antagonistes contre la proteine bcrf1 destines au traitement d'infections provoquees par le virus d'epstein-barr |
WO1993011157A1 (fr) * | 1991-11-27 | 1993-06-10 | The Council Of The Queensland Institute Of Medical Research | VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX) |
WO1995004075A1 (fr) * | 1993-07-28 | 1995-02-09 | Medvet Science Pty. Ltd. | Antagonistes de facteurs de croissance hematopoietique |
WO1995019568A1 (fr) * | 1994-01-14 | 1995-07-20 | Matthias Rath | Oligopeptides signaux hydrophiles et leurs procedes d'utilisation a des fins therapeutiques |
WO1997026279A1 (fr) * | 1996-01-18 | 1997-07-24 | Steeno Research Group A/S | Analogues synthetiques d'il-10 |
Non-Patent Citations (1)
Title |
---|
M. RATH: "Cationic-anionic and anionic-cationic oligopeptides in apoprotein-A and other proteins as modulators of protein action and of biological communication", JOURNAL OF APPLIED NUTRITION, vol. 44, no. 3-4, 1992, LA HABRA US, pages 62 - 69, XP002051963 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431384B2 (en) | 2004-05-24 | 2013-04-30 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
US8283165B2 (en) | 2008-09-12 | 2012-10-09 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
US8951719B2 (en) | 2008-09-12 | 2015-02-10 | Gentegra, LLC. | Matrices and media for storage and stabilization of biomolecules |
Also Published As
Publication number | Publication date |
---|---|
EP0929568A2 (fr) | 1999-07-21 |
AU4132097A (en) | 1998-04-02 |
NZ335039A (en) | 2001-04-27 |
SE9900812D0 (sv) | 1999-03-08 |
CN1230195A (zh) | 1999-09-29 |
JP2001503613A (ja) | 2001-03-21 |
AU6887096A (en) | 1998-04-02 |
IL128806A0 (en) | 2000-01-31 |
WO1998010792A1 (fr) | 1998-03-19 |
WO1998010787A2 (fr) | 1998-03-19 |
SE9900812L (sv) | 1999-03-08 |
CA2265885A1 (fr) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998010787A3 (fr) | Therapie a but immunitaire | |
CA2282300A1 (fr) | Poxvirus recombine destine a une immunisation contre l'antigene associe aux tumeurs muc1 | |
WO2000034317A3 (fr) | Modification de l'immunogenicite de proteines | |
US20190292231A1 (en) | Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom | |
WO2015109931A1 (fr) | Protéine de fusion tim-3 humaine capable de bloquer une voie de signalisation tim-3 | |
CA2224257A1 (fr) | Poxvirus recombines du raton laveur et leur utilisation en tant que vaccin efficace contre l'infection par le virus de l'immunodeficience feline | |
JPH07503851A (ja) | 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法 | |
KR20010030563A (ko) | 인터페론 칸센서스 및 인터루킨-1 수용체 길항물질을 포함하는 다발성경화증을 치료하기 위한 제약학적 조성물 | |
EP0262710A1 (fr) | Utilisation d'un peptide pour la préparation de compositions pour le soulagement, le traitement ou le diagnostique de maladies autoimmunes, notamment des affections arthritiques, et de composés dérivés dudit peptide, des microorganismes synthétisant ledit peptide ou de composés dérivés dudit peptide, ainsi que des compositions pharmaceutiques et diagnostiques et des kits de tests | |
US10884000B2 (en) | Method of monitoring the efficacy of the anti-clever-1 therapy in cancer | |
US7618935B2 (en) | Chaperonin 10 immunosuppression | |
WO2023169115A9 (fr) | Vecteur de vaa ayant une affinité élevée avec le système nerveux et son utilisation | |
JP2010535504A5 (fr) | ||
US20030198624A1 (en) | Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer | |
Paveglio et al. | The tick salivary protein, Salp15, inhibits the development of experimental asthma | |
WO2003018606A3 (fr) | Peptides derives de la caseine et leurs utilisations therapeutiques | |
JPH01104021A (ja) | 血小板第4因子のペプチドフラグメントを含む組成物及び抑制免疫応答を回復させる方法 | |
WO2001059073A3 (fr) | Lymphocytes t cytotoxiques actives par des hybrides de cellules dendritiques | |
WO1998022580A3 (fr) | Proteine immunotrope (cd14) associee a la lactation bovine, gene codant celle-ci et application de cette proteine dans une activation de lymphocytes b | |
WO2010079511A4 (fr) | Nanopeptides dérivés d'un colostrum mammalien pour infections virales et récurrentes à large spectre avec leur procédé d'isolement | |
CA2196416A1 (fr) | Virus herpetique de recombinaison avec promoteur du gene gb | |
US10822395B2 (en) | Modified anti-inflammatory proteins and method of use | |
RU2076715C1 (ru) | Способ получения препарата "аффинолейкин" для противоинфекционной иммунотерапии | |
EP1575614A1 (fr) | Proteines recombinees de parapoxvirus ovis et compositions pharmaceutiques produites a partir de celles-ci | |
AU1156001A (en) | Recombinant therapeutic fusion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97197816.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
ENP | Entry into the national phase |
Ref document number: 2265885 Country of ref document: CA Ref document number: 2265885 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 99008120 Country of ref document: SE |
|
WWP | Wipo information: published in national office |
Ref document number: 99008120 Country of ref document: SE |
|
ENP | Entry into the national phase |
Ref document number: 1998 513435 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 335039 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997939105 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997939105 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09254626 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997939105 Country of ref document: EP |